Immix Biopharma News - IMMX

Company Name	Stock Ticker Symbol	Market	Type
Immix Biopharma Inc	IMMX	NASDAQ	Common Stock

	Price Change	Change Percent	Stock Price	Last Traded
	-0.03	-1.41%	2.10	20:00:00

Open Price	Low Price	High Price	Close Price	Prev Close
2.15	2.02	2.2899	2.10	2.13

more quote information »

Recent News

Date	Time	Source	Heading
4/25/2024	8:52	IHNW	FeaturedCannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA
2/07/2024	17:15	EDGAR2	Form 424B5 - Prospectus [Rule 424(b)(5)]
2/06/2024	09:09	EDGAR2	Form 8-K - Current report
2/05/2024	16:38	EDGAR2	Form 424B5 - Prospectus [Rule 424(b)(5)]
2/05/2024	16:37	EDGAR2	Form 8-K - Current report
12/12/2023	18:25	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
11/28/2023	10:48	IHNW	Immix Biopharma Announces FDA Approval of IND Application..
11/09/2023	19:57	EDGAR2	Form 4/A - Statement of changes in beneficial ownership of..
9/25/2023	16:15	EDGAR2	Form S-3 - Registration statement under Securities Act of..
9/18/2023	19:03	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
9/15/2023	18:27	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
9/12/2023	16:58	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
8/30/2023	16:15	EDGAR2	Form SC 13D - General statement of acquisition of beneficial..
8/23/2023	16:28	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
8/22/2023	16:05	EDGAR2	Form 8-K - Current report
8/14/2023	16:15	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
8/14/2023	16:15	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
8/14/2023	16:15	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
8/14/2023	16:15	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
8/11/2023	16:30	EDGAR2	Form 10-Q - Quarterly report [Sections 13 or 15(d)]
7/25/2023	08:42	GLOBE	Immix Biopharma Subsidiary Nexcella Announces NXC-201..
7/17/2023	09:37	GLOBE	Immix Biopharma Reports 2nd Positive Interim Clinical Trial..
7/14/2023	17:28	EDGAR2	Form 424B5 - Prospectus [Rule 424(b)(5)]
7/14/2023	17:26	EDGAR2	Form 8-K - Current report
7/10/2023	09:47	GLOBE	Immix Biopharma Subsidiary Nexcella Completes Initial..
6/26/2023	09:49	GLOBE	Immix Biopharma Subsidiary Nexcella Completes Pre-IND..
6/22/2023	09:53	GLOBE	Immix Biopharma Subsidiary Nexcella Appoints Edward J...
6/20/2023	09:45	GLOBE	Immix Biopharma Subsidiary Nexcella Appoints Jeffrey H...
6/16/2023	09:43	GLOBE	Immix Biopharma Subsidiary Nexcella Appoints Mary Sue..
6/14/2023	07:30	GLOBE	Immix Biopharma Completes $5 Million At-The-Market Equity..
6/12/2023	09:49	GLOBE	Immix Biopharma Subsidiary Nexcella Appoints Henry..
5/26/2023	09:53	GLOBE	Immix Biopharma Subsidiary Nexcella Announces Commencement..
5/21/2023	16:05	GLOBE	Nexcella Announces Positive NXC-201 Clinical Results at..
5/21/2023	16:00	GLOBE	Immix Biopharma Announces Positive NXC-201 Clinical Results..
5/04/2023	12:30	GLOBE	Immix Biopharma Announces Late-Breaking NXC-201 Clinical..
5/03/2023	08:00	GLOBE	Immix Biopharma Announces Early Positive IMX-110 Interim..